Advances in the management of myeloma bone disease

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 16, 2005, Pages 2781-2791

  Shipman, Claire M ^a   Oyajobi, Babatunde O ^a   Mundy, Gregory R ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Bisphosphonate; Multiple myeloma; Osteoblast; Osteoclast; RANKL

Indexed keywords

ALPHA4 INTEGRIN ANTIBODY; AMGN 0007; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CLODRONIC ACID; CYTOKINE RECEPTOR ANTAGONIST; DENOSUMAB; DEXAMETHASONE; FRIZZLED RELATED PROTEIN 2; HUMAN MONOCLONAL ANTIBODY; IBANDRONIC ACID; LORON; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA ANTIBODY; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DKK1; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR ANTIBODY; OSTEOPROTEGERIN; PAMIDRONIC ACID; PROTEIN DICKKOPF 1; RECOMBINANT OSTEOPROTEGERIN CONSTRUCT; RISEDRONIC ACID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; WNT PROTEIN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE DISEASE; BONE NECROSIS; CANCER STAGING; CANCER SURVIVAL; CELL GROWTH; CELL INTERACTION; CELL SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; FRACTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUALITY OF LIFE; RECEPTOR BINDING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STROMA CELL; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

ANIMALS; BONE NEOPLASMS; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; MULTIPLE MYELOMA;

EID: 29444435275     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.16.2781     Document Type: Review

References (94)

1. VALENTIN OA, CHARHON SA, MEUNIER PJ, EDOUARD CM, ARLOT ME: Quantitative histology of myeloma-induced bone changes. Br. J. Haematol. (1982) 52:601-610.
2. TAUBE T, BENETON MN, MCCLOSKEY EV et al.: Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur. J. Haematol. (1992) 49:192-198.
3. BATAILLE R, CHAPPARD D, MARCELLI C et al.: Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest. (1991) 88:62-66.
4. EVANS CE, GALASKO CS, WARD C: Does myeloma secrete an osteoblast inhibiting factor? J. Bone Joint Surg. Br. (1989) 71(2):288-290.
5. BATAILLE R, DELMAS PD, CHAPPARD D, SANY J: Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer (1990) 66(1):167-172.
6. ABILDGAARD N, RUNGBY J, GLERUP H et al.: Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur. J. Haematol. (1998) 61(2):128-134.
7. WOITGE HW, HORN E, KECK AV et al.: Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin. Chem. (2001) 47(4):686-693.
8. MUNDY GR: Myeloma bone disease. Eur. J. Cancer (1998) 34:246-251.
9. MUNDY GR, RAISZ LG, COOPER RA, SCHECHTER GP, SALMON S: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med. (1974) 291:1041-1046.
10. GARRETT IR, DURIE BG, NEDWIN GE et al.: Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N. Engl. J. Med. (1987) 317(9):526-532.
11. KAWANO M, HIRANO T, MATSUDA T et al.: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 332:83-85.
12. LEE JW, CHUNGHY, EHRLICH LA et al.: IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood (2004) 103(6):2308-2315.
13. LICHTENSTEIN A, BERENSON J, NORMAN D, CHANG MP, CARLILE A: Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood (1989) 74(4):1266-1273.
14. FLEISCH H: Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs (1991) 42(6):919-944.
15. HUGHES D, WRIGHT KR, UY H et al.: Bisphosphonates promote apoptosis in routine osteoclasts in vitro and in vivo. J. Bone Miner. Res. (1995) 10:1478-1487.
16. LUCKMAN SP, HUGHES DE, COXON FP et al.: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. (1998) 13(4):581-589.
17. RODAN CA, FLEISCH HA: Bisphosphonates: mechanisms of action. J. Clin. Invest. (1996) 97:2692-2696.
18. LAHTINEN R, LAAKSO M, PALVA I, VIRKKUNEN P, ELOMAA I: Randomised, placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet (1992) 340:1049-1052.
19. MCCLOSKEY EV, MACLENNAN IC, DRAYSON MT et al.: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br. J. Haematol. (1998) 100:317-325.
20. BERENSON J, LICHTENSTEIN A, PORTER L et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. (1996) 334:488-493.
21. BRINCKER H, WESTIN J, ABILGAARD N et al.: Failure of oral parmidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br. J. Haematol. (1998) 101:280-286.
22. MAJOR P, LORTHOLARY A, HON J et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. (2001) 19(2):558-567.
23. ROSEN LS, GORDON D, KAMINSKI M et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. (2001) 7(5):377-387.
24. BERENSON JR, ROSEN LS, HOWELL A et al.: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 91(7):1191-1200.
25. MENSSEN HD, SAKALOVA A, FONTANA A et al.: Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markets in patients with advanced multiple myeloma. J. Clin. Oncol. (2002) 20(9):2353-2359.
26. TERPOS E, VINIOU N, DE LA FUENTE J et al.: Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur. J. Haematol. (2003) 70(1):34-42.
27. ROUX C, RAVAUD P, COHEN-SOLAL M et al.: Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone (1994) 15:41-49.
28. BERENSON JR, HILLNER BE, KYLE RA et al.: American Society of Clin. Oncol. clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. (2002) 20(17):3719-3736.
29. MCCLOSKEY EV, MACLENNAN IC, DRAYSON M et al.: Effect of clodronate on morbidity and mortality in myelomatosis. Ann. Oncol. (1996) 7:4120 (Abstract).
30. MUSTO P, FALCONE A, SANPAOLO G et al.: Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk. Lymphoma (2003) 44(9):1545-1548.
31. CAPARROTTI G, CATALANO L, FEO C et al.: Perspective study on pamidronate in stage I multiple myeloma. Hematol. J. (2003) 4(6):459-460.
32. SHIPMAN CM, ROGERS MJ, APPERLEY JF, RUSSELL RG, CROUCHER PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br. J. Haematol. (1997) 98(3):665-672.
33. SHIPMAN CM, CROUCHER PI, RUSSELL RG, HELFRICH MH, ROGERS MJ: The bisphosphonate incadronate (YM175) causes apoprosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. (1998) 58:5294-5297.
34. GORDON S, HELFRICH MH, SATI HI et al.: Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br. J. Haematol. (2002) 119(2):475-483.
35. KUNZMANN V, BAUER E, FEURLE J et al.: Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood (2000) 96:384-392.
36. SHIPMAN CM, VANDERKERKEN K, ROGERS MJ et al.: The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. Br. J. Haematol. (2000) 111(1):283-286.
37. DALLAS SL, GARRETT IR, OYAYOBI BO et al.: Ibandronate reduces osteolytic lesions but not tumour burden in a murine model of myeloma bone disease. Blood (1999) 93:1697-1706.
38. CROUCHER PI, DE HENDRIK R, PERRY MJ et al.: Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. (2003) 18(3):482-492.
39. YACCOBY S, PEARSE RN, JOHNSON RN et al.: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on ostoeclast activity. Br. J. Haematol. (2002) 116:278-290.
40. BERENSON JR, LICHTENSTEIN A, PORTER L et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. (1998) 16:593-602.
41. SEZER O, JAKOB C, ZAVRSKI I et al.: Bisphosphonates in early multiple myeloma. Eur. J. Haematol. (2003) 71(3):231-232.
42. RUGGIERO SL, MEHROTRA B, ROSENBERG TJ, ENGROFF SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. (2004) 62(5):527-534.
43. MARX RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. (2003) 61(9):1115-1117.
44. HOFF AO, TOTH B, ALTUNDAG K et al.: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J. Bone Miner. Res. (2005) 20(Suppl. 1):1218 (Abstract).
45. KUT V, MEHTA J, TARIMAN J, OLSSON A, SINGHAL S: Osteonecrosis of the jaw in myeloma patients receiving pamidronate or zoledronate. Blood (2004) 104(11):4933 (Abstract).
46. DURIE BG, KATZ M, CROWLEY J: Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. (2005) 353(1):99-102.
47. HELLSTEIN JW, MAREK CL: Bisphosphonate osteochemonecrosis (bisphossy jaw): is this phossy jaw of the 21st century? J. Oral Maxillofac. Surg. (2005) 63(5):682-689.
48. ANDERSON DM, MARASKOVSKY E, BILLINGSLEY WL et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 390:175-179.
49. LACEY DL, TIMMS E, TAN HL et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 93:165-176.
50. SIMONET WS, LACEY DL, DUNSTAN CR et al.: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell (1997) 89:309-319.
51. KONG Y-Y, YOSHIDA H, SAROSI I et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 397:315-323.
52. LI J, SAROSI I, YAN XQ et al.: RANK is the intrinsic hematopoictic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA (2000) 97(4):1566-1571.
53. MIZUNO A, AMIZUKA N, IRIE K et al.: Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. (1998) 247:610-615.
54. PEARSE RN, SORDILLO EM, YACCOBY S et al.: Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote rumor progression. PNAS (2001) 98(20):11581-11586.
55. GIULIANI N, BATAILLE R, MANCINI C, LAZZARETTI M, BARILLÉ S: Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood (2001) 98(13):3527-3533.
56. ROUX S, AMAZIT L, MEDURI G et al.: RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am. J. Clin. Pathol. (2002) 117(2);210-216.
57. SEIDEL C, HJERTNER Ø, ABILDGAARD N et al.: Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood (2001) 98(7):2269-2271.
58. POLITOU M, TERPOS E, ANAGNOSTOPOULOS A et al.: Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br. J. Haematol. (2004) 126(5):686-689.
59. TERPOS E, SZYDLO R, APPERLEY JF et al.: Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood (2003) 102(3):1064-1069.
60. FARRUGIA AN, ATKINS GJ, TO LB et al.: Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. (2003) 63(17):5438-5445.
61. SHIPMAN CM, HOLEN I, LIPPITT JM, VANDEBERGHE E, CROUCHER PI: Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. Blood (2000) 96:360a.
62. SHIPMAN CM, CROUCHER PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. (2003) 63:912-916.
63. CROUCHER PI, SHIPMAN CM, LIPPITT J et al.: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 98(13):3534-3540.
64. VANDERKERKEN K, DE LEENHEER E, SHIPMAN C et al.: Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. (2003) 63(2):287-289.
65. OYAJOBI BO, MUNDY GR: Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer (2003) 97(3 Suppl.):813-817.
66. BODY J-J, GREIPP P, COLEMAN RE et al.: A Phase I study of AMGN-00007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 97(3 Suppl.):887-892.
67. BEKKER PJ, HOLLOWAY DL, RASMUSSEN AS et al.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. (2004) 19(7):1059-1066.
68. TERPOS E, POLITOU M, SZYDLO R et al.: Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br. J. Haematol. (2003) 123(1):106-109.
69. CHOI SJ, CRUZ JC, CRAIG F et al.: Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood (2000) 96(2):671-675.
70. OBA Y, LEE JW, EHRLICH LA et al.: MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp. Hematol. (2005) 33(3):272-278.
71. OYAJOBI BO, FRANCHIN G, WILLIAMS PJ et al.: Dual eflects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 102(1):311-319.
72. CHOI SJ, OBA Y, GAZITT Y et al.: Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J. Clin. Invest. (2001) 108(12):1833-1841.
73. MOON RT, KOHN AD, DEFERRARI GV, KAYKAS A: Wnt and b-catenin signalling: disease and therapies. Nat. Rev. Genet. (2004) 5(9):691-701.
74. GONG Y, SLEE RB, FUKAI N et al.: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 107(4):513-523.
75. KATO M, PATEL M, LEVASSEUR R et al.: Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistant embryonic eye vascularization in mice deficient in LRP5, a Wnt coreceptor. J. Cell Biol. (2002) 157(2):303-314.
76. TIAN E, ZHAN F, WALKER R et al.: The role of the Wnt-signaling antagonist in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. (2003) 349(26):2483-2494.
77. RAWADI G, VAYSSIERE B, DUNN F, BARON R, ROMAN-ROMAN S: BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J. Bone Miner. Res. (2003) 18(10):1842-1853.
78. TIAN E, IANG Y, YACCOBY S et al.: Toward the elucidation of the role of altered Wnt signaling in myeloma and development of therapeutic interventions based on these findings. Haematologica (2005) 90(Suppl. 1):44.
79. OSHIMA T, ABE M, ASANO J et al.: Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 106(9):3160-3165.
80. OKADO T, HAWLEY RG: Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int. J. Cancer (1995) 63(6):823-830.
81. 1-VCAM-1 interaction. Bone (1998) 23:S180.
82. 1-integrin enhances production of osteoclast-stimulating activity. Blood (2000) 96:1953-1960.
83. MORI Y, SHIMIZU N, DALLAS M et al.: Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood (2004) 104(7):2149-2154.
84. OLSON DL, BURKLY LC, LEONE DR, DOLINSKI BM, LOBB RR: Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther (2005) 4(1):91-99.
85. GOLDBERG AL, ROCK K: Not just research tools-proteasome inhibitors offer therapeutic promise. Nat. Med. (2002) 8(4):338-340.
86. RICHARDSON PG, BARLOGIE B, BERENSON J et al.: Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood (2005) 106(9):2977-2981.
87. YANG HH, VESCIO R, SCHENKEIN D, BERENSON JR: A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma. Clin. Lymphoma (2003) 4(2):119-122.
88. JAGANNATH S, BARLOGIE B, BERENSON JR et al.: Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer (2005) 103(6):1195-1200.
89. JAGANNATH S, DURIE BG, WOLF J et al.: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. (2005) 129(6):776-783.
90. RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348(26):2609-2617.
91. GARRETT IR, CHEN D, GUTIERREZ G et al.: Selective inhibitors of the osteoblast proteasome, stimulate bone formation in vivo and in vitro. J. Clin. Invest. (2003) 111(11):1771-1782.
92. OYAJOBI BO, GARRETT IR, GUPTA A et al.: Role of Dickkopf 1(Dkk) in myeloma bone disease and modulation by the proteasome inhibitor velcade. J. Bone Miner. Res. (2004) 19(1):1011.
93. ZANGARI M, BARLOGIE B, CHOON-KEE L et al.: Increment in bone phosphatase (ALP) in myeloma during treatment with Velcade, Thalidomide and dexamethasone (VTD) is a strong predictor of response. Blood (2003) 102:687a.
94. ZAVRSKI I, KREBBEL H, WILDEMANN B et al.: Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem. Biophys. Res. Commun. (2005) 333(1):200-205.